- Home
- SNPX vs CERO Comparison
SNPX vs CERO Comparison
Compare SNPX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- CERO
- Stock Information
- Founded
- SNPX 2012
- CERO 2017
- Country
- SNPX United States
- CERO United States
- Employees
- SNPX N/A
- CERO N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- CERO
- Sector
- SNPX Health Care
- CERO
- Exchange
- SNPX Nasdaq
- CERO Nasdaq
- Market Cap
- SNPX 3.1M
- CERO 3.5M
- IPO Year
- SNPX N/A
- CERO N/A
- Fundamental
- Price
- SNPX $4.64
- CERO $9.93
- Analyst Decision
- SNPX Strong Buy
- CERO Strong Buy
- Analyst Count
- SNPX 1
- CERO 2
- Target Price
- SNPX N/A
- CERO $45.00
- AVG Volume (30 Days)
- SNPX 2.7M
- CERO 3.3M
- Earning Date
- SNPX 08-13-2025
- CERO 08-13-2025
- Dividend Yield
- SNPX N/A
- CERO N/A
- EPS Growth
- SNPX N/A
- CERO N/A
- EPS
- SNPX N/A
- CERO N/A
- Revenue
- SNPX N/A
- CERO N/A
- Revenue This Year
- SNPX N/A
- CERO N/A
- Revenue Next Year
- SNPX N/A
- CERO N/A
- P/E Ratio
- SNPX N/A
- CERO N/A
- Revenue Growth
- SNPX N/A
- CERO N/A
- 52 Week Low
- SNPX $1.84
- CERO $6.71
- 52 Week High
- SNPX $6.19
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SNPX 63.57
- CERO 50.09
- Support Level
- SNPX $3.25
- CERO $8.12
- Resistance Level
- SNPX $4.44
- CERO $13.14
- Average True Range (ATR)
- SNPX 0.87
- CERO 2.83
- MACD
- SNPX 0.04
- CERO 0.39
- Stochastic Oscillator
- SNPX 80.22
- CERO 19.58
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.